NICE in draft guidance requires more information from Santen for Ikervis (ciclosporin eye drops) to treat keratitis

The National Institute of Care and Clinical Excellence (NICE) guidance does not recommend ciclosporin eye drops within its marketing authorisation, for treating severe keratitis in adults with dry eye disease, which has not improved despite treatment with tear substitutes. Further analyses are required from the company. NICE concluded that it needed additional evidence from the company which should include: 1. An indirect comparison of the clinical effectiveness of ciclosporin plus corticosteroids (if needed) and artificial tears, and that of corticosteroids (if needed) and artificial tears. 2. An economic model comparing the cost effectiveness of ciclosporin plus corticosteroids (if needed) and artificial tears, with that of corticosteroids (if needed) and artificial tears.